Connect with us

BUSINESS

Oura Buys Counsel Health for $625 Million After IPO

Oura is spending $625 million in cash on Counsel Health six weeks after pulling its IPO, buying doctors while its ring is still not a medical device.

Published

on

Oura agreed on November 10, 2026, to pay $625 million in cash for Counsel Health, whose doctors already chat inside the Oura app. The ring maker had postponed a Nasdaq listing of up to $2.2 billion six weeks earlier, on September 29, 2026.

The purchase spends more cash than Oura itself would have raised in new shares, and the ring still carries a notice that it is not a medical device.

Oura Spends More Cash Than Its IPO Would Have Raised

The listing Oura pulled was marketed at $40 to $44 a share on 50 million shares. Only 13.5 million of those shares were new. At the top of the range the company would have taken in $594 million. At the bottom, $540 million. Existing holders were selling the other 36.5 million shares, or 73% of the deal.

Oura is now writing a larger check than that primary raise, and it is writing it in cash. Executive chairman David Shuman tied the spend to a quarter that, on preliminary unaudited figures, produced $533 million of revenue, up 153%, and $87 million of adjusted EBITDA, a 16% margin. Fiscal 2026 revenue was about $1.75 billion, up 92%. He put the membership base at more than six million, up from 5.7 million paid members when the IPO was paused.

Over the past 10 years, our ring has gotten smaller and our platform has gotten bigger. Oura’s record growth of 153 percent this quarter and our over six million members provides us the confidence to invest $625 million cash to acquire Counsel Health.

David Shuman, executive chairman of Oura, company announcement

The last private round, in October 2025, valued Oura at $11 billion after more than $900 million of late-stage capital. The pulled IPO would have implied $15.6 billion at the top of the range. Chief executive Tom Hale said at the time that Oura had “the luxury of choosing our moment.” The moment it chose was a clinic.

THE CHECK AGAINST THE IPO OURA WALKED AWAY FROM

Item Figure
Cash Oura is paying for Counsel $625 million
New shares Oura would have sold in the IPO $540 million to $594 million
Counsel capital raised (seed plus Series A) $36 million
Oura fiscal 2026 revenue (preliminary) $1.75 billion

Counsel had disclosed $36 million of funding. The cash price is 17 times that sum. Healthcare investor Christina Farr wrote that Counsel had been in the market raising, with momentum, and got bought instead. She asked the question the announcement does not answer: what multiple of Counsel’s revenue that $625 million represents.

A Two-Minute Doctor Now Lives in the Oura App

Counsel is a three-year-old medical group, founded in 2023 by Dr. Muthu Alagappan, a Stanford-trained physician and former chief medical officer at Notable Health who also attended at Massachusetts General Hospital and UCSF. Members start in chat with Counsel’s medical AI, which pulls connected records, prior visits, clinical guidelines, and Oura body data. At any point they can add a board-certified Counsel physician who can diagnose, prescribe, and refer. On Counsel’s own consumer app, that add-on is priced at $29.

Alagappan said the care line has an 80 NPS, an average physician response time of two minutes, and 96% of medical concerns handled without escalation. Partnerships with health plans, health systems, consumer health groups, and employers have made Counsel available to more than 8 million Americans. Among Oura members already using Counsel, more than 90% of those surveyed said their Oura data helped them get better care, and members who saw a physician rated the visit 4.6 out of 5.

Andreessen Horowitz, which led Counsel’s seed and co-led its Series A with GV, described the company as a full-stack, AI native medical group built to make doctor time less scarce. Julie Yoo and Jay Rughani wrote that more than 100 million people in the United States have no dedicated doctor, and that Counsel’s job is clinical resolution (the prescription, the lab, the referral), not another chatbot. Counsel announced a $25 million Series A with a16z in October 2025, after an $11 million seed in October 2024, and said then that the model saved $381 a year per engaged member.

The official Counsel account posted the sale as a way to multiply clinical capacity and keep serving health plans after the close.

Oura and Counsel say they will extend the in-app path across three lines of care.

THREE CARE LINES INSIDE THE OURA APP

  • Preventive care: Flag changes from continuous ring data and move a member into clinical guidance before a scheduled visit.
  • Acute care: Route a headache, a rash, or a similar flare to medical AI and, if needed, a physician who can prescribe the same day.
  • Specialty and chronic care: Keep a running relationship for reproductive health, aging, and cardiometabolic conditions, including labs and referrals.

That is a medical practice sitting on top of a consumer subscription, not a sleep score with a help button. The ring already stores how little someone slept. The next step is a doctor reading that file in the same thread.

The Clinic Talks Started While the IPO Was Live

Alagappan said the two teams “bonded over a joint vision, shared culture, and mission, further solidifying as we negotiated our deal over the past few months.” Counsel’s service went into the Oura app in June 2026. Oura’s public S-1 landed on September 3. The IPO was pulled 26 days later. The clinic talks were live across that window.

Hale’s pause statement sold patience. The registration was never declared effective. Bookbuilding had finished. Pricing was due the evening of September 29, with Nasdaq trading the next day under the ticker OURA. Oura said demand was strong and still walked. Public-market buyers were being asked to pay up for hardware growth that one buyside adviser, speaking around the pull, framed as one Apple or Google product away from trouble. A wearable that also bills for visits is a different story, and a harder one to take public in the same breath as a ring launch.

HOW THE CLINIC AND THE IPO OVERLAPPED

  1. October 2024: Counsel raises $11 million in seed funding led by Andreessen Horowitz.
  2. October 2025: Counsel closes a $25 million Series A co-led by a16z and GV. Oura raises more than $900 million at an $11 billion valuation.
  3. May 2026: Oura Ring 5 goes on sale at $399, 40% smaller than the model it replaced.
  4. June 2026: Counsel’s medical AI and physicians go live inside the Oura app.
  5. September 17, 2026: Counsel joins a Medicare chronic-care program with Oura as its wearable partner.
  6. September 29, 2026: Oura postpones the Nasdaq listing hours before pricing.
  7. November 10, 2026: Oura signs a definitive agreement to buy Counsel for $625 million in cash, with a close due before the end of 2026.

Staying private let Oura spend operating cash and last year’s round on a care company instead of arguing with IPO accounts about how much of the next year’s growth was already in the price. It also left the secondary sellers who wanted out in September still on the cap table.

Medicare Patients Are Already on the 2027 Calendar

The deeper shift is who pays. On September 17, 2026, Counsel said it would join the Centers for Medicare & Medicaid Services Innovation Center’s 10-year ACCESS chronic care model on the early cardio-kidney-metabolic track. Starting in early 2027, Counsel will deliver AI-native chronic care for hypertension, obesity, hyperlipidemia, and prediabetes at no out-of-pocket cost to eligible Medicare beneficiaries in nearly all U.S. states.

Oura’s role in that program is narrower than the acquisition headline. The Oura app will promote the program and pass interested members to Counsel. Counsel physicians confirm eligibility and run the care. Members who wear a ring and consent can have their Oura data folded into the chart. Members who do not wear a ring can still enroll. Dr. Rishi Khakhkhar, Counsel’s chief medical officer, said chronic care has to move from an episodic visit to something always on. Dr. Ricky Bloomfield, Oura’s chief medical officer, said ACCESS lets the two companies study ring data plus physician care at Medicare scale.

The CMS model itself began on July 5, 2026, and runs through June 30, 2036. Participating groups get recurring payments for managing qualifying conditions, with full payment tied to measured outcomes such as a drop in blood pressure. Counsel is walking Oura into that payment file. An Oura spokesman has also said the ring is already a covered benefit for eligible members of Essence Healthcare, a Medicare Advantage plan. Twenty percent of Oura members aged 65 and older have a BMI of 30 or higher, which is why the obesity track is not a side quest for this membership.

Once those Medicare visits are inside Oura, the company’s competitive set is no longer only other rings. It includes virtual medical groups, health-plan triage lines, and whoever else CMS lets into ACCESS.

Why the Ring Still Is Not a Medical Device

The same announcement that boasts about prescriptions still prints a hard limit on the hardware. “Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.” Hale is selling the opposite motion in the next paragraph of the same release: members move from an Oura insight to a chat, then to a doctor who can write a script.

Oura helps members understand their physiology and, with Counsel, they can take action on their health across a range of needs, from quick questions and prescriptions to lab results, chronic care, and referrals. Together, we can create a new model of care that extends the current healthcare paradigm by delivering an experience that’s more immediate, personalized, and proactive. This is a massive step in our mission to empower people to live healthier, longer, by delivering on the promise of a 24-7 doctor in your pocket.

Tom Hale, chief executive officer of Oura, company announcement

Alagappan built Counsel around a different safety claim: physicians stay in the loop for clinical decisions, and specialized agents handle history-taking, guideline lookup, records review, and emergency flags before a doctor is pulled in. He is joining Oura. The Counsel team is moving with him. The legal split remains. The ring collects. The clinic acts. If a recommendation is wrong, the liability sits with the medical group Oura is about to own, not with a consumer gadget that still refuses the word diagnose.

That split is also why a close before the end of 2026 is not a software merge. Counsel is a licensed practice. State medical boards, corporate-practice rules, and ordinary purchase-price adjustments all sit between signature and close. Oura is paying $625 million in cash, subject to those adjustments.

Health Plans Do Not Have to Buy the Ring

Counsel’s enterprise book is the part of the deal that does not need a finger. Alagappan told partners that Counsel’s platform will not require anyone to have or purchase Oura Rings. Health plans and employers keep the same chat-and-physician front door. Consumer users of Counsel’s own app were told they can keep using it for new symptoms, everyday questions, and ongoing primary and chronic care, with more detail promised in the coming weeks.

Shuman’s case for the price is lifetime value on Oura’s more than six million members, plus that outside funnel. Hale’s case is a doctor in the pocket. The ironic residue of the IPO is simpler. Oura had a buyer for old shares in September and said no. In November it became the buyer, of a clinic, with cash, at a number that exceeds what new Oura stock would have brought in, while the object on the finger is still, by Oura’s own line, not a medical device.

The companies expect the deal to close before the end of 2026, subject to customary conditions. Until then the $29 doctor add-on still sits one tap away from the sleep score.

Disclaimer: This article is news reporting and analysis of a corporate transaction and related product claims. It is informational only and does not constitute medical advice, a diagnosis, or investment advice, and it is not a recommendation to buy, hold, or sell any security or to use, switch, or stop any health service, wearable, or prescription. Readers with health questions should consult a licensed physician or other qualified clinician, and readers making financial decisions should consult a licensed financial adviser who can review their own facts. Figures, membership counts, and deal status are drawn from company announcements and other sources as of November 10, 2026, and may change as the purchase closes, as audits finish, and as regulators or clinicians review the combined service.

Harry is the editor of BUDGY APP, an independent title he owns and runs after ten years in journalism that began on a reporter's desk and ended up at the editor's. Numbers get particular attention here. A percentage in a business story is recomputed from the underlying figures before it goes live, a benchmark in a technology or gaming review is quoted with the conditions it was measured under, and a transfer fee or a lap time in the sports and auto pages is traced back to the club, the league or the timing sheet that published it. The same rule covers news, science, entertainment, lifestyle and travel: if a figure cannot be tied to a filing, a dataset, a transcript or a test Harry ran himself, it does not appear. Readers around the world see prices in the original currency with a conversion alongside. Errors are corrected in the open under a published corrections policy, with the change noted on the article. Questions about any figure reach him at support@budgyapp.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending